Diabetes Solutions Landscape, US Phase 2, Part 2

Part
01
of five
Part
01

Diabetes Solutions Landscape KPI - One Drop

One Drop is a cloud-based diabetes management solution that helps to monitor, analyze and provide online real-time blood glucose data of diabetes patients through mobile device platforms.

According to report, One Drop ranks among the top Health and Fitness apps and has generated over 500 million health data points by its users globally.
Private and government health insurance companies does not offer reimbursement for One Drop solutions. The total amount raised by the company from inception was estimated $14.1 million.
The full details of the requested information have been completed in row 8: One Drop, columns T-AO on the US tab of the attached spreadsheet.

Part
02
of five
Part
02

Diabetes Solutions Landscape KPI - Noom

Noom has not been endorsed or recognized by the medical associations or regulatory bodies defined as such by the parameters of this request. However, it has been endorsed by the US Center for Disease Control (CDC); it has an aggregate of 45 million users; and it appears to have a high overall level of user satisfaction across both the Android and iOS app platforms. All relevant details, sources and methodology explanations can be found in the spreadsheet. We have further clarified our logic for KPI 1 below.


KPI 1: The absence of medical device approval or endorsement was based on the lack of any press release from the company website detailing such an approval or endorsement. Our research indicates that the US CDC is neither a regulatory body, nor a medical association. Our research found no indication in either press release archives or third-party analyses that Noom has a medical device classification.


Part
03
of five
Part
03

Diabetes Solutions Landscape KPI - Azumio Fitness Buddy

No reimbursements or partnerships were found for Azurnia Fitness Buddy. They received Series A funding that totalled $3.4 million. The app has received 2.762 million downloads on Google Play Store and is offered in 31 languages. The app has a high, overall rating of 4.5out of 5 with over 30,000 reviews. I've provided all the details on KPIs for Fitness Buddy, with the appropriate sources, in the attached spreadsheet.
Part
04
of five
Part
04

Diabetes Solutions Landscape KPI - My Net Diary Diabetes and Blood Glucose Tracker

The MyNetDiary Diabetes and Blood Glucose Tracker, in conjunction with the MyNetDiary weight lose and diet program, was launched in 2007 by 4Technologies Corporation. In 2012, the company changed its name to MyNetDiary. The attached spreadsheet, row 14, contains an overview of KPIs associated with the product.

Findings

-The MyNetDiary Diabetes and Blood Glucose Tracker has not been approved by the FDA or any other medical association.
-After extensively searching the company's website, industry reports, and reports about the reimbursement of mobile apps, we found no indication that reimbursement is taking place either by a public or private payer. Currently, mobile apps and mHealth is growing faster than health care providers and other stakeholders can keep up with.
-MyNetDiary was launched by an already established company and no seeding or funding was necessary.
-The app was downloaded by 16,065 users in the last 30 days. The entire program boasts over 5 million registered users.
-The tracker is available in English only.
-User ratings were 4.6 out of 5 stars for both the iOS version and Android version.
-No official statistics are published regarding the impact on diabetes. In general, the average weight loss is 27 lbs. in 221 days. User reviews indicate that the tracker has reduced the number of diabetes medications needed.

Conclusion

An overview of KPIs associated with the MyNetDiary Diabetes and Blood Glucose tracker has been organized in the attached spreadsheet, row 14.
Part
05
of five
Part
05

Diabetes Solutions Landscape KPI - Glooko

Glooko, a diabetes management app, is an FDA-approved blood sugar tracking tool that has helped over a million patients working with 6,000 health providers. As requested, a more comprehensive look into the apps Key Performance Indicators (KPI) has been detailed in row 15, columns T-AO of the attached spreadsheet.

FINDINGS
Glooko received FDA approval in January 2013 for its diabetes management app. More recently, the app received FDA clearance for its long-acting insulin titration system.

Medicare covers chronic care management since January 2015, which includes solutions like Glooko. A recent change in the policy uncovered US$251,000 per provider per year for remote monitoring.

Glooko's latest round of founding, its Series C, obtained US$43 million from two investors. The app has received a total investment of US$71 million. According to figures provided by Glooko to TechCrunch, the app has helped over a million patients through 6,000 providers.

Glooko is, as of April 2018, available only in English.

The level of user satisfaction is high, with average rate in Google Play reaching 4 stars (out of 726 reviews) and average rate in iTunes reaching 3.5 stars (out of 17 reviews).

Glooko claims that its insights provide actionable results, and have led to 16% increase in glucose testing, 10.7% decrease of probability of hyperglycemic events and 10% decrease of probability of hypoglycemia (this last figure in 60% of its users).

CONCLUSION
To wrap up, KPIs for health solution Glooko, such as number of users, ratings and funding, have been entered in row 15, columns T-AO of the attached spreadsheet.
Sources
Sources